Prof. Kazuo Koyanagi (National Cancer Center, Japan) presented the initial results [1]. The 3-arm JCOG 1109 trial (UMIN000009482) is evaluating the overall survival benefit of DCF and CF-RT compared with standard CF as preoperative therapy in patients with thoracic oesophageal cancer. The primary analysis for the trial is planned for 2023; the current analysis focused on the impact on perioperative complications with the 3 neoadjuvant regimens as the impact of preoperative therapy for oesophageal cancer has not been fully investigated yet.
Patients with stage IB/II/III thoracic oesophageal cancer (n=601) were randomised equally to 1 of 3 arms to receive neoadjuvant chemotherapy prior to transthoracic oesophagectomy with regional lymphadenectomy:
- In the control arm (arm A), patients received cisplatin 80 mg/m2 on day 1 plus 5-FU at 800 mg/m2 on days 1 to 5 of the 3-week cycle for 2 cycles.
- Patients in arm B received cisplatin 70 mg/m2 on day 1, 5-FU 700 mg/m2 on days 1 to 5, and docetaxel 70 mg/m2 on day 1 every 3 weeks for 3 cycles.
- Arm C received cisplatin 75 mg/m2 on day 1 with 5-FU 1,000 mg/m2 days 1 through 4 every 4 weeks for 2 cycles in addition to radiation therapy at a total of 41.4 Gy.
The incidence of postoperative complications did not significantly increase with DCF or CF-RT. The rate of grade 3/4 pneumonia was 7.6% in arm A, 5.5% in arm B, and 6.2% in arm C. Grade 3/4 leakage was observed in 3.2% in arm A, 6.6% in arm B, and 7.3% in arm C. The rate of recurrent laryngeal nerve paralysis was 3.2%, 1.6%, and 1.7% in arms A, B, and C, respectively. Postoperative complications of any kind and of grade 2 or higher in severity were observed more in the CF arm (56.2%) compared with the DCF arm (43.7%; P=0.02) and compared with the CF-RT arm (47.8%; P=0.11).
“From these results we could at least say preoperative DCF or CF-RT did not increase the risk of postoperative complications,” Prof. Koyanagi concluded.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC Next Article
Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma »
« Ipilimumab/nivolumab plus panitumumab in patients with microsatellite-stable mCRC Next Article
Final phase 2 results of second-line infigratinib for advanced cholangiocarcinoma »
Related Articles
October 23, 2019
Global burden of digestive diseases reveals alarming trends
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com